Innovent Biopharmaceutical Transformation
Innovent's First 10 Years Growth: A Solid Track Record
$
7
25
commercial
products
clinical
assets
60000L
25
6100
capacity in
operation
global
partnerships
experienced
talents
2021 total product
revenue over RMB 4bn
• Accumulated sales of
TYVYT over RMB 6.4bn
since launch with
continuous satisfactory
growth momentum
6 assets in NDA or
pivotal trials
19 assets in Phase I
and Il stages
• 80+ research
programs in pre-
clinical stage
• 60K liter capacity in
operations. Additional
172K liter capacity
under construction
• World-class CMC
Strategic collaboration
with MNCs e.g. Eli Lilly
and Roche
Partnership with regional
and global biotechs
• 1,500+ R&D
• 1,300+ CMC
~3,000 sales &
marketing
Transformed from a biotech start-up to a leading biopharma company in China
Innovent
Confidential
Copyright©2022 InnoventView entire presentation